083790.KQライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 7月 2024 @ 14:22):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
本日の出来高	68 508
平均出来高	199 147
時価総額	206.35B
EPS	KRW-98.15 ( Q1 \| 2024-03-31 )
次の収益日	( KRW0 ) 2024-08-14
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW3.69 (0.13%)

相関 (AI algo v.1.1b): Undervalued: 0.03% KRW2 780.78 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.12 (neutral)

短: 0.89 (strong)

Signal:(75.182) Same movement expected

CrystalGenomics, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CrystalGenomics, Inc. 相関 - 通貨/商品

-0.41
( neutral )

0.36
( neutral )

-0.79
( moderate negative )

-0.26
( neutral )

-0.67
( moderate negative )

0.66
( moderate )

CrystalGenomics, Inc. 財務諸表

Annual	2023
収益:	KRW4.88B
総利益:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
収益:	KRW4.88B
総利益:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
収益:	KRW17.46B
総利益:	KRW9.07B (51.96 %)
EPS:	KRW132.36

FY	2022
収益:	KRW16.25B
総利益:	KRW8.47B (52.13 %)
EPS:	KRW117.19

Financial Reports:

No articles found.

CrystalGenomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CrystalGenomics, Inc.

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.